Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Diabetes Metab J (2016) 40(2):99114
Rival incretin-based therapies from Novo Nordisk, including semaglutide-based blockbusters Ozempic and Wegovy, continue to anchor the market, although Eli Lilly has been taking the edge with its tirzepatide products Mounjaro and Zepbound
Lets take cravings, for instance
Sureshan M, Prabhu D, Kadhirvel S (2022) Computational identification and experimental validation of anti-filarial lead molecules targeting metal binding/substrate channel residues of Cu/Zn SOD1 from Wuchereria bancrofti
US$ 20.58
US$ 20.68
US$ 28.77
US$ 21.39
US$ 28.03
US$ 26.07
